2-fluorofucose

Generic Name: 2-fluorofucose

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₁FO_₄

CAS Number: 70763-62-1

Unique Ingredient Identifier: W39886N0ZG

Background: 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Breast Neoplasms
Urinary Bladder Neoplasm
Carcinoma, Squamous Cell of Head and Neck
Colorectal Neoplasms
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: SGN-2FF
Drug: pembrolizumab

First Posted Date: 2016-11-02

Last Posted Date: 2019-07-19

Lead Sponsor: Seagen Inc.

Target Recruit Count: 47

Registration Number: NCT02952989

Locations: 🇺🇸
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

and more 8 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy